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Abstract
The ability of ultrasonically-induced oscillations of circulating microbubbles to permeabilize vascular barriers such as the
blood-brain barrier (BBB) holds great promise for noninvasive targeted drug delivery. A major issue has been a lack of
control over the procedure to ensure both safe and effective treatment. Here, we evaluated the use of passively-recorded
acoustic emissions as a means to achieve this control. An acoustic emissions monitoring system was constructed and
integrated into a clinical transcranial MRI-guided focused ultrasound system. Recordings were analyzed using
a spectroscopic method that isolates the acoustic emissions caused by the microbubbles during sonication. This analysis
characterized and quantified harmonic oscillations that occur when the BBB is disrupted, and broadband emissions that
occur when tissue damage occurs. After validating the system’s performance in pilot studies that explored a wide range of
exposure levels, the measurements were used to control the ultrasound exposure level during transcranial sonications at
104 volumes over 22 weekly sessions in four macaques. We found that increasing the exposure level until a large harmonic
emissions signal was observed was an effective means to ensure BBB disruption without broadband emissions. We had
a success rate of 96% in inducing BBB disruption as measured by in contrast-enhanced MRI, and we detected broadband
emissions in less than 0.2% of the applied bursts. The magnitude of the harmonic emissions signals was significantly
(P,0.001) larger for sonications where BBB disruption was detected, and it correlated with BBB permeabilization as
indicated by the magnitude of the MRI signal enhancement after MRI contrast administration (R
2=0.78). Overall, the results
indicate that harmonic emissions can be a used to control focused ultrasound-induced BBB disruption. These results are
promising for clinical translation of this technology.
Citation: Arvanitis CD, Livingstone MS, Vykhodtseva N, McDannold N (2012) Controlled Ultrasound-Induced Blood-Brain Barrier Disruption Using Passive Acoustic
Emissions Monitoring. PLoS ONE 7(9): e45783. doi:10.1371/journal.pone.0045783
Editor: Arrate Mun ˜oz-Barrutia, University of Navarra, Spain
Received April 27, 2012; Accepted August 24, 2012; Published September 24, 2012
Copyright:  2012 Arvanitis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health award numbers R25 CA089017 and RC2NS069413. The focused ultrasound system was
supplied by InSightec. Additional support was provided by a gift from Betty Brudnick. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: A pending patent (#21379) on the method presented (US Provisional application # 61/548,274 filed on October 18, 2011.) The focused
ultrasound system was supplied by InSightec. There are no further products in development or marketed products to declare. This does not alter the authors’
adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: cda@bwh.harvard.edu
Introduction
Vascular barriers play an important role in the delivery of
therapeutics, and can be a significant impediment to effective drug
delivery. This is particularly important in the brain, where the
blood brain barrier (BBB) excludes most molecules from being
delivered from the bloodstream and precludes the use of many
drugs [1] for central nervous system (CNS) applications. A number
of strategies have been investigated to overcome the BBB,
including direct drug injection/infusion [2], trans-arterial infusion
of agents such as mannitol to transiently disrupt the BBB [3,4] or
by developing new drug formulations that can cross the BBB [5,6].
These approaches are either invasive, not targeted, or require the
development of novel drugs or drug carriers.
A promising noninvasive approach to deliver drugs past the BBB
is the use of focused ultrasound with microbubbles, which can
inducetargetedBBBdisruptionforafewhoursandallowdrugstobe
delivered to the brain [7]. This method utilizes mechanical
interactions between the microbubbles oscillating in the ultrasound
field and the vasculature, leading to a transient disassembly of tight
junctioncomplexesandtheinductionofactivetransport[8,9].Ifthis
approachcanbescaleduptohumanuseandeffectivelycontrolled,it
could have a large impact on CNS therapeutics.
Past work has identified a relatively narrow window in acoustic
pressure amplitude where BBB disruption can be safely achieved
[10,11]. Without adequate control of the sonications, the
ultrasound exposures (sonications) can create excessive forces in
proximity to the oscillating microbubbles, leading to vascular
damage [12], or in very small oscillations, leading to insufficient
local perturbation and lack of the desired effect [10]. Moreover, it
is difficult in practice to precisely predict (e.g. within the safety
window) the acoustic pressure amplitude produced by any
administered ultrasound acoustic power in vivo, particularly when
sonicating transcranially. Vascularity, vessel diameter, blood flow
and other properties also vary substantially across different
structures of the brain, which can impact the local concentration
of microbubbles, how they interact with the ultrasound field, and
how much drug will be delivered to the brain [13]. These
uncertainties, along with the nonlinear response of microbubbles
[14,15], makes control critical for the utilization and clinical
translation of this technique.
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e45783The acoustic emissions from the oscillating microbubbles offer
characteristic signatures that allow for remote assessment of the
mode of oscillations [16] and offer a potential way to guide and
monitor microbubble-enhanced ultrasound therapies such as BBB
disruption [10,11,17,18]. The spectral content and strength of the
emissions can be used to monitor the micro-scale perturbations. In
particular, microbubbles vibrating in an ultrasound field (‘‘stable
cavitation’’) can exert direct forces on the endothelium through
oscillatory and radiation forces. They also can exert indirect shear
forces [18,19] induced by micro-streaming [20] in the fluid that
surrounds them. Presumably these forces produced during stable
cavitation are responsible for the observed BBB disruption [10,11].
Strong harmonic and/or sub- and ultra-harmonic acoustic
emissions in the absence of broadband signal are indicative of such
stable volumetric oscillations [21,22]. At higher pressure ampli-
tudes the microbubble oscillations deviate significantly from the
equilibrium radius and become unstable. At a high enough
pressure amplitude, the microbubble can collapse violently due to
inertia of the surrounding medium, which can produce large shear
stresses, shock waves [23], elevated temperatures [24], and, when
the collapse happens in proximity to interfaces (e.g. vascular walls),
micro-jets [25,26] and membrane perforation [12,27]. This
collapse, termed ‘‘inertial cavitation’’ [28], creates a pressure spike
[29] that is manifested in the frequency domain of the acoustic
emission as a broadband signal. Inertial cavitation has been
associated with tissue damage [30].
The purpose of this work was to integrate an acoustic emissions
monitoring system into a clinical transcranial MRI-guided focused
ultrasound (TcMRgFUS) system and to evaluate its use for
controlling BBB disruption in non-human primates. The system
uses harmonic and broadband emissions, signatures of the
effectiveness of the ultrasound to disrupt the BBB and of tissue
damage, respectively [10]. We have utilized a spectroscopic
method for monitoring the acoustic emissions [31] that largely
isolates the emissions arising from microbubble activity. This
analysis, along with the design of the monitoring system, aimed to
maximize its sensitivity to the harmonic and broadband emission
signals, which are small compared to the fundamental frequency of
the TcMRgFUS device, particularly when sonicating transcra-
nially. The system was characterized in pilot studies over a wide
range of exposure levels. It was then used during tests evaluating
the safety of repeated BBB disruption sessions in macaques [32],
where it was used to control the procedure. Here, we report on the
success of this control, which aimed to reliably induce MRI-
detectable BBB disruption without the production of broadband
emissions. We also evaluated whether the strength of the harmonics
emissions was predictive of whether or not BBB disruption was
produced, and if its strength could predict its magnitude. Finally,
we explored strategies to increase the strength of the harmonic
emissions, and presumably the magnitude of the BBB disruption.
These experiments, in which the operator used the acoustic
emissions analysis to manually adjust the exposure level at each
target in each animal, aimed to investigate whether this system and
analysis can form a basis for the future development of an
automated, computer-based real-time controller.
Materials and Methods
Ultrasound Device
The ultrasound fields were generated by a clinical TcMRgFUS
system (ExAblate 4000 low frequency, InSightec Ltd, Haifa, Israel)
originally developed for high-intensity sonications for tissue
ablation [33]. This system uses a phased array with 1024 elements
arranged in a 30 cm diameter hemisphere with a central
frequency of 220 kHz. It was operated in burst mode via a gating
signal provided by an arbitrary waveform generator (model 396,
Fluke, Norwich, UK), which also triggered the acquisition for the
system used to monitor acoustic emissions. The TcMRgFUS
system was integrated with a clinical 3T MRI unit (GE
Healthcare, Milwaukee, WI). Imaging was performed using
a 15 cm diameter surface coil (constructed in house). The
TcMRgFUS array faced upwards (i.e. rotated 90u from its normal
use in patients [34]) and was filled with degassed water. The
animal was placed supine on the MRI scanner table with its head
tilted backwards so that the top of the head was submerged in
water (Fig. 1A).
The driving system of the TcMRgFUS system allows for
individual control of the phase and amplitude for each element in
the phased array so the beam can be steered several cm in each
direction, enabling targeting of different brain regions without
moving the transducer. The steering range of the transducer was
sufficient to cover the entire brain in a monkey. During the
experiments the beam can be steered to different targets during
a single sonication. In this way multiple ‘‘subsonications’’ can be
delivered in sequence to multiple locations in a single sonication.
The acoustic power can be set individually for each of these
subsonications. The phased array is also used to correct for skull-
induced beam aberrations [35]. These corrections were not
performed in these experiments, as they use modeling based on
CT scans of the skull, which were not available to us at the time of
these experiments. Note however that only limited beam
aberration is expected at this frequency (220 kHz) [36].
The half-intensity profile of the focal region in water was
provided by the manufacturer and in the lateral and axial
directions were approximately 3.0 and 5.8 mm, respectively.
Reported values for the ultrasound exposure levels are in vivo
estimates of the peak negative pressure amplitude (referred
throughout as simply ‘‘pressure amplitude’’). To estimate the in
vivo pressure amplitude, measurements were first obtained in
water in the free field as a function of the acoustic power using
a 4 mm diameter, calibrated, omni-directional hydrophone (TC
4038, Reson Inc, Slangerup, Denmark). To estimate the effects of
a monkey’s skull on the pressure amplitude, we degassed
a desiccated rhesus macaque skull in water for several days. The
insertion loss due to this skull was measured at multiple positions
with this hydrophone and a single-element FUS transducer
(diameter/radius of curvature: 10/8 cm) operating at 257 kHz.
The drop in pressure amplitude due to the monkey skull was
25614%. Attenuation from brain tissue and skin were not
considered, as their impact would be less than 5% at 220 kHz.
Based on these measurements, an acoustic power level of 1 W was
estimated to produce a pressure amplitude of 223 kPa in the brain.
Other pressure amplitudes were estimated by extrapolation
assuming linear propagation. Note that this pressure amplitude
estimate did not include effects arising from variations in skull
bone thickness for different animals, variability in skull orientation
within the TcMRgFUS system, or decreases in pressure amplitude
that occur when the focal point is steered electronically away from
the geometric focus. These effects were expected to contribute
uncertainty to our pressure amplitude estimates. The presence of
standing waves may have added additional uncertainty. While we
have not observed evidence of significant standing waves such as
BBB disruption in the beam path [32], they may have been
present with this device at a low level [37,38].
Sonications
Similar to prior work [7], the sonications consisted of 10 ms
bursts applied at a low pulse repetition frequency (PRF). For
Controlled Blood Brain Barrier Disruption
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sonication) in our pilot studies, a 1 Hz PRF was used. For multi-
target sonications, the beam was steered sequentially to nine
subsonication targets arranged in a 363 grid in a single plane with
a 200 ms interval (Fig. 1B). This interval was the fastest that the
FUS device could be programmed to sonicate different targets in
sequence, which reduced the duty cycle per subsonication target.
The pattern was repeated every 1.8 s, yielding a PRF at each
location of 0.55 Hz. Three 50 s sonications were delivered in
sequence with a delay between sonications of ,25 s (Fig. 1C). This
delay was imposed by the TcMRgFUS system software, which
limited the sonication duration to 50 s when such multi-target
sonications were employed. The subsonications were set 2 mm
apart with an aim of creating a volume of BBB disruption of
approximately 1 cm
3.
Except where specified, a single acoustic power level was used
during each burst and subsonication target during each multi-
target sonication. The power level used varied for the different
Figure 1. Experimental setup and methods. (A) Coronal T2-weighted MRI of a monkey obtained during one of the experiments. The image has
been annotated to show the location of the 30 cm diameter hemisphere transducer, the two transducers that served as receivers to monitor the
acoustic emissions, and the MRI surface coil. The annotations were drawn to scale with the location of the brain in a typical position. (B) Beam
steering pattern used during the multi-target sonications. The order of the sonications delivered is indicated. (C) Pulsing scheme used during the
multi-target sonications. Each 10 ms burst was applied in sequence to the different subsonication targets every 200 ms. The pattern was repeated
every 1.8 s, resulting in a pulse repetition frequency at each target of 0.55 Hz. Three 50 s sonications were delivered in series using this pattern, with
a 25 second delay between sonications. The microbubbles were administered as an infusion that was started at the beginning of the each multi-
target sonication, as indicated. This infusion was delivered at a variable rate in order to quickly reach a steady-state microbubble concentration in the
tissue and maintain it throughout the entire sonication.
doi:10.1371/journal.pone.0045783.g001
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based on online measurements of the acoustic emissions, as we
describe below. Before any microbubbles were administered, each
target was sonicated for 25 s without microbubbles using identical
parameters. These ‘‘baseline’’ sonications were used in the acoustic
emissions analysis, as described below.
For BBB disruption, each sonication was combined with an
infusion of microbubble ultrasound contrast agent. The micro-
bubble agent Definity (Lantheus Medical Imaging, N. Billerica,
MA) was infused over the entire sonication via an MRI-compatible
infusion pump (Spectra Solaris EP, Medrad, Warrendale, PA).
The microbubble agent was diluted in 5 ml sterile phosphate-
buffered saline. The infusion was administered at a variable rate.
The first 1 ml was administered at 0.1ml/s for 10 s. The
remaining 4 ml was infused at a slower rate of 0.02 ml/s for
200 s (Fig. 1C). This infusion protocol was employed in order to
rapidly reach a steady-state tissue concentration of microbubbles,
and then maintain it throughout the entire sonication. The
infusion started simultaneous with the sonication, which enabled
us to observe the change in acoustic emissions when the
microbubbles arrived at the focal region. Except where specified,
a dose of 20 ml/kg of Definity was used for each infusion. The time
between sonications at different locations within the brain was
typically 2 min. This time allowed most of the microbubbles to be
cleared from the vasculature.
Acoustic Emissions Monitoring System
The acoustic emissions were recorded for every 10 ms burst
(Fig. 1C) with two MRI-compatible piezoelectric transducers,
which were constructed in-house for this study. Since the skull
attenuates high ultrasound frequencies, receive transducers sensi-
tive at frequencies below 1 MHz were selected for recording the
emissions. We aimed to have maximum sensitivity to broadband
emissions, which can be smaller in magnitude than the funda-
mental frequency or harmonics of the TcMRgFUS device during
BBB disruption [10]. This sensitivity was achieved using filtration
to reduce the fundamental frequency and through the use of
sharply-tuned receive transducers with a resonant frequency of
approximately 610620 kHz. This frequency lies between the third
harmonic (660 kHz) and the fifth ultraharmonic (550 kHz) of the
TcMRgFUS device. The two transducers were rectangular, air-
backed, and weakly focused (radius of curvature: 15 cm). The
piezoelectric element of each transducer was made of lead
zirconate titanate and had dimensions of 7640 mm. The 23d B
of the sensitivity profile of the transducers (measured at 610 kHz
with a needle hydrophone) were 100, 24, and 6 mm in the axial
and the two transverse dimensions, respectively, with maximum
sensitivity at 75 mm away from the transducer face. Each
transducer was mounted in an acrylic housing (dimensions:
56261 cm). The transducers were mounted in the water in the
beam path of the TcMRgFUS device on each side of the head,
approximately 10 cm from the geometrical focus of the hemi-
spherical phased array (Fig. 1A). Their effect on the beam path
was assumed to be negligible. At 10 cm from the focal point, the
FUS beam transverses a hemisphere with a surface area of
628 cm
2. With a cross-sectional area in the beam path of 5 cm
2
each, the transducers blocked less than 2% of the transmitted field,
therefore their effect on the beam should be minor. The
transducers were connected to the data acquisition system through
the penetration panel of the MRI room with approximately 10 m
coaxial cables.
Two filtering/amplification schemes were evaluated. One
transducer was connected to a 20 dB gain low-noise preamplifier
and a 250–1000 kHz band-pass filter (EC 6081, Reson Inc,
Slangerup, Denmark). The other was connected to a 125–
390 kHz band-reject filter with a 40 dB gain (Model 3944,
Krohn-Hite Corp, Brockton, MA, USA). The signals were
recorded using a high-speed digitizing card (NI PXI-5124
National Instruments, Austin, Texas, USA) that had 512 MB
onboard memory per channel, 12 bit resolution, and a maximum
sampling rate of 200 Ms/s. The digitizer was driven by an 8 core,
2.53 GHz PC with 12 GB memory (Dell Precision T7500, Round
Rock, Texas, USA) and was able to transfer the data at a speed of
800 MB/s. The system was controlled using software developed
in-house in Matlab (Mathworks, Natick, MA, USA).
The voltage traces measured by the receive transducers from
the entire 10 ms burst were recorded for every sonication. The
data was digitized at a Nyquist frequency of 5 MHz, well above
the frequency components of the recorded emissions and the
sensitivity of our recording transducers. The spectral resolution
was 100 Hz. The control software displayed both time and
spectral data, which was obtained via fast-Fourier transform
(FFT), from both detectors in real-time. To decrease spectral
leakage, a Hanning window was applied to the time-series data
before computing the FFT. MRI was not performed during the
acoustic emissions acquisitions to avoid artifacts induced by the
scanner.
Acoustic Emission Analysis
The central concept has been to develop a spectroscopic
approach to evaluate the microbubbles’ emissions while minimiz-
ing the influence of background signals arising from linear and
nonlinear components of the transmitted and reflected acoustic
wave produced by the TcMRgFUS device and from background
electronic noise. During the sonications the acoustic emissions
captured with the two transducers are a mixture of many sources
that need to be decoupled from activity at BBB disruption site,
presumably at the focal region. This was achieved by taking the
ratio of the acoustic emissions with microbubbles to that obtained
during identical sonications without microbubbles.
To obtain the spectral decomposition needed to evaluate
microbubble response in different frequency bands, the power
spectral density (PSD) of the digitized RF signals recorded from
the passive cavitation detectors was calculated. The PSD of
a discrete time series of data sk :dt ðÞ is expressed in units of
V
2Hz
21 and is given by:
PSD f ðÞ ~D
1
N
X N{1
k~0
sk :dt ðÞ e{i2pf:k:dtD
2, ð1Þ
Where f~n:df is the discrete frequency interval n in which the
PSD is evaluated, df~1=N:dt is the spectral resolution (100 Hz
here), 1=dt is the sampling frequency (1n here), and k~0,1,2,:::N,
where N is the time-series length (10
5 here). The PSD measured
from the acoustic emissions during the sonications incorporates
microbubble emissions, the transmitted wave from the FUS
transducer, from reflections of this wave from the tissue, and
harmonic waves due to nonlinear sound propagation. Electronic
noise from surrounding equipment will also be present. The
recorded signal is modulated by the frequency response of the
transducers. All these components confound the analysis of the
power spectrum and interfere with accurate assessment and
characterization of the microbubble oscillations.
In order to separate these sources from the microbubble
emissions, we obtained background acoustic emissions at every
target in identical sonications applied before any sonication with
microbubbles. We then determined the relative power spectral
Controlled Blood Brain Barrier Disruption
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RPS(fn)~
PSDtot fn ðÞ
PSDbs fn ðÞ
, ð2Þ
where PSDtot fn ðÞ is the total recorded energy per frequency bin
during the sonication, PSDbs fn ðÞis the recorded power per
frequency bin in the absence of microbubbles (bs stands for
‘‘baseline’’ signal). The relative signal strengths of the harmonic
and ultraharmonic emissions can be determined from the log
transformed RPSD. Reported values are the mean of the first
three harmonics (440, 660, and 880 kHz) and ultra-harmonics
(330, 550, and 770 kHz). For broadband emissions, a frequency
band around the resonance frequency of the receiving transducers
(610 kHz) was used. A log transform was performed to simplify the
statistical analyses; otherwise the emission measurements were not
normally distributed. The strength of the acoustic emissions is
summarized in the following equation
S~
1
m
X m
i~1
1
l
X l
j~1
X n
k~1
Ln RPSD fn ðÞ ðÞ :dfn, ð3Þ
where m is the number of waveforms that were averaged together
(typically 75 for harmonics; 1 for ultraharmonic and broadband
signals), l is the number of spectral bands analyzed (3 for
harmonic/ultraharmonic peaks, one for broadband signal), and n
is the number of discrete frequency bands used for each
measurement. For harmonic and ultraharmonic emissions, n was
five, which corresponded to five points in the discretized spectrum
that covered a frequency band of about 6250 Hz. For broadband
emissions, n was 100, which corresponded to a frequency band of
65 kHz. The units of S are Np:Hz.
The emissions produced during sonication with microbubbles
are likely to be small and will be attenuated by the skull. It is
therefore important to determine whether the measurement at
each frequency band is significantly above the noise of the RPSD.
Thus, in addition to calculating the relative signals (harmonics,
ultraharmonics, broadband), we also calculated the signal-to-noise
ratio (SNR). The noise for each measurement was
N~
std Ln RPSD fn ðÞ ðÞ ðÞ
ﬃﬃﬃﬃﬃﬃﬃ
l:m
p
ﬃﬃﬃ
n
p
, ð4Þ
where l,m, and n are defined in Eq. 3. It was evaluated at
1150 kHz in the same way as the broadband noise. This was
a region of the spectrum that no signal related to microbubble
emission was observed. We used a conservative SNR of 3 to
classify an emission as significantly above the noise floor.
In processing the recordings, we treated the measurements from
the two receiving transducers as equivalent; reported values for
each sonication are from the transducer that had the larger signal.
This was possible because despite using different filtration
schemes, the measurements for the two transducers were found
to be correlated, and the measurements on average were the same.
Linear regression of the harmonic emissions signal strength
(defined above) for the two transducers showed a good correlation
(R
2: 0.65), and the two signals were found to be not significantly
different (P,0.05) using a paired t-test.
The use of an infusion for the microbubble administration
resulted in a harmonic signal that was steady over time over most
of the sonication and enabled us to use an ensemble of spectral
data in Eq. 3 to increase accuracy in harmonic signal measure-
ments per location. During the multi-target sonications, typically
the last 75 waveforms were averaged together for each subsonica-
tion target. When broadband or ultraharmonic emissions were
observed, they were often sporadic and variable in magnitude, so
instead of averaging the data, the maximum relative broadband
signal of all waveforms were computed.
Animals
All experiments were done in accordance with procedures
approved by the Harvard Medical School Institutional Animal
Care and Use Committee. The animals were anesthetized during
all the procedures and were constantly monitored throughout and
after recovery. No pain or suffering was evident as a result of the
procedures. Monkeys were housed, fed, watered, socially housed,
and provided with environmental enrichment according to U.S.
Department of Agriculture (USDA), Office of Laboratory Animal
Welfare (OLAW), and Association for Assessment and Accredita-
tion of Laboratory Care (AAALAC) regulations.
Acoustic emission measurements were obtained in six maca-
ques. Pilot studies to explore a large range of power levels were
performed on monkeys #1–2. Monkey #2 was euthanized after
the experiments, and the sonicated locations were examined in
histology, as described below. The sonications in monkeys #3–6
were part of a survival study on the safety of repeated BBB
disruption [32] (see below for details).
Monkeys #1–5 were adult rhesus macaques (three male, one
female, weight: 7–13 kg); monkey #6 was a juvenile nemestrina
macaque (male, 3.75 kg). Each animal was anesthetized with
ketamine (15 mg/kg/h i.m.) and xylazine (0.5 mg/kg/h i.m.), or
with 4 mg/kg/h ketamine and Dexmeditomidine (0.01–0.02 mg/
kg/h i.m.) and intubated. The head was shaved, and a catheter
was placed in a leg vein. During the procedure the heart rate,
blood oxygenation levels, and rectal temperature were monitored.
Body temperature was maintained with a heated water blanket.
MR Imaging and Analysis
MRI was performed before the animal experiments to localize
the focus of the TcMRgFUS device in the MRI image space.
During the experiments it was used for treatment planning to
select the brain targets and after treatment to assess the treatment
(BBB disruption and tissue damage). During the sonications, no
MRI was performed; the treatment was controlled solely using
acoustic emissions as described above.
Before each experiment, the location of the ultrasound beam in
the MRI coordinate-space was found by visualizing focal heating
in an FUS/MRI phantom using MR temperature imaging [39].
Then the animal was placed on the FUS system, and MRI was
used in order to select identify the different brain targets for
sonication. We used a 3D fast spoiled gradient echo sequence with
inversion recovery preparation (TR/TE/TI: 5.3/2.0/600 ms, FA:
10u, FOV: 12 cm, matrix: 1286128, slice thickness: 2 mm) or
a multi-slice T2-weighted Fast Spin Echo (FSE) sequence (TR/
TE: 4500/85.8 ms; echo train length, ETL: 8; field of view, FOV:
12 cm; matrix: 2566256, slice thickness: 3 mm) for this planning.
Different targets were selected with the aid of an MRI atlas of the
rhesus macaque brain [40].
At the end of each session (a few minutes after the last
sonication), we acquired T1-weighted FSE images (TR/TE: 500/
14 ms; ETL: 4; FOV: 12 cm; matrix: 2566256, slice thickness:
3 mm). These images were repeated after the administration of the
MRI contrast agent Gd-DTPA (Magnevist, Berlex Laboratories,
Inc., Wayne NJ) at a concentration of 0.1 mmol/kg of body
weight as a bolus injection through the leg vein. This contrast
agent normally does not extravasate into the brain, and signal
Controlled Blood Brain Barrier Disruption
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regions of BBB disruption. A 3D T2*-weighted spoiled gradient
echo sequence (TR/TE: 33/19 ms; FA: 15u; FOV: 12 cm; matrix:
2566256; slice thickness: 1 mm) was used to detect vascular
damage. This sequence shows hypointense regions induced by tiny
red blood cell extravasations (petechaie) that occur presumably
due to inertial cavitation [7]. T2-weighted FSE imaging was also
acquired after sonication.
The contrast-enhanced T1-weighted images were scored as
enhancing or not by an author who was blind to the acoustic
emissions analysis. This author also compared the T2*-weighted
images acquired before and after sonication and scored each
targeted region as having or not having hypointense spots. Images
and plots of MRI contrast enhancement show the percent signal
enhancement relative to pre-contrast imaging.
Experimental Protocols
Pilot studies. Experiments were performed in monkeys #1–
2 to characterize the acoustic emissions monitoring system over
a relatively wide range of exposure levels, including those that
produced significant broadband emission, a signature for inertial
cavitation. We aimed to verify that the system functioned as
expected based on prior work in small animals. We aimed to verify
that the harmonic emissions occurred at a lower pressure
amplitude than broadband emissions and to confirm that the
system could detect low-level broadband emissions which have
been correlated with the production of minor vascular damage
(petechaie) [10,11]. To minimize the amount of brain damage
induced by the exposures, single-target sonications were per-
formed during these tests.
In monkey #1, we evaluated the acoustic emissions as a function
of the peak negative pressure amplitude. During these sonications,
the acoustic power increased with every burst (between 0.4 and 4
W in 10 steps). This range corresponded to estimated pressure
amplitudes in the brain of 140–440 kPa. This cycle was repeated 4
times for each sonication. We then identified the threshold for
harmonic, ultraharmonic, and broadband emissions with an
SNR.3. Four targets were sonicated with this scheme in the
amygdala in this animal. This structure was targeted in order to
establish applicability for deep brain targets.
Tests were performed in monkey #2 to investigate the
sensitivity of our detectors to low-level broadband emissions. Here
we sonicated at 10 targets in the cingulate cortex at different
pressure amplitudes. Five different exposure levels were tested
between 0.3 and 1.5 W (estimated pressure amplitude in the brain:
125, 175, 210, 245 and 275 kPa); each exposure level was tested at
two targets. The cingulate cortex was selected because it is an
anatomically large and homogeneous gray matter target that is
aligned with the axial MRI planes. This monkey was sacrificed
approximately two hours after the last sonication for histological
examination. The animal was deeply anesthetized with ketamine
(15 mg/kg i.m.), given an overdose of pentothal (100 mg/kg), and
then perfused transcardially with 1 L 0.9% NaCl, followed by 2 L
10% buffered formalin phosphate). The brain was removed and
bisected midsagitally, cut into approximately 4 mm thick axial
slabs, and photographed. The sonicated regions were identified
and extracted from these slabs into 262 cm blocks, and then cut
into a series of 5-mm-thick paraffin-embedded sections. Every 40th
section was stained with hematoxylin and eosin (H&E) and Nissl to
evaluate whether extravasated red blood cells (petechaie) or other
tissue damage were present.
Acoustic emissions-based control. Monkeys #3–6 are part
of an ongoing survival study where repeated BBB disruption was
produced in targets in the visual system followed by functional/
behavioral tests [32]. In each animal, the lateral geniculate nucleus
(LGN) and the foveal confluence of primary visual cortex and
secondary visual areas were sonicated in both hemispheres in five
weekly sessions. Additional locations centered on the cingulate
cortex which included adjacent white matter were targeted
specifically for the present study (see below for details). Each
target in these animals utilized multi-target sonications, and every
sonicated volume included both gray and white matter structures.
Targets in the visual cortex also often included sulci, and some
overlapped the brain surface.
The acoustic emissions were used to control the acoustic power
level at the different targets in each animal. Strong harmonic
emissions were tested as a signature for BBB disruption, and
broadband emissions were considered signatures for overexposure
and a risk for vessel damage. The control was performed
manually. In the first session in each animal a conservative power
level was used, which was selected based on our estimates for the
pressure amplitude in the monkey brain described above, prior
work in small animals that evaluated BBB disruption thresholds
[41], and our experience in earlier sessions. If at this initial power
level we did not observe an increase in harmonic emissions in at
one or more of the subsonication targets that was at least one to
two orders of magnitude larger than the baseline emission
obtained earlier without microbubbles, the power was increased
and the sonication repeated. This procedure was repeated at each
target in each animal. Over the following weeks, this power level
was used as a starting point, with minor week-to-week increases or
reductions employed if later detailed offline analysis revealed weak
harmonic emissions and/or contrast enhanced MR signal
enhancement or broadband signal was detected. Overall, 114
volumes were sonicated over the course of these 22 experiments in
monkeys #3–6. The acoustic power level ranged from 0.2–1.9 W,
which yielded an estimated pressure amplitude in the brain 100–
300 kPa. The applied acoustic power varied among the different
brain targets and animals (Table 1), with larger animals generally
requiring higher levels to achieve strong harmonic emissions.
To test how well this control worked in ensuring BBB disruption
without producing broadband emission, we counted the number
of multi-target sonications that resulted in evident contrast
enhancement in MRI after Gd-DTPA administration in at least
one subsonication target in the LGN and visual cortex sonications.
These two structures were included in this analysis as we always
aimed to produce BBB disruption in them (some cingulate cortex
and other targets used lower power levels to evaluate the acoustic
emissions below the BBB disruption threshold). We also counted
the number of subsonications and individual 10 ms bursts where
broadband emissions with an SNR greater than 3 were evident.
Acoustic Emissions vs. MRI
After the experiments in monkeys #3–6, the acoustic emissions
data was compiled and compared retrospectively to MRI exams
obtained immediately after the sonications. First, we examined
whether the strength of the harmonic emissions was predictive of
the onset for BBB disruption. This examination was performed on
all of the targets sonicated in monkeys #3–6. BBB disruption at
each target was ascertained by the presence or absence of signal
enhancement in T1-weighted MRI after the injection of Gd-
DTPA. The binary (Yes/No) outcome of the contrast enhanced
MR image assessment was compared to the strength of the
harmonic signals recorded during the sonications. The subsonica-
tion with the maximum harmonic emissions signal was used for
this analysis.
Next, we investigated whether the strength of the harmonic
emissions was predictive of the level of the BBB disruption. Here,
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subsonication targets to the corresponding signal enhancement
after Gd-DTPA administration. Due to the three-dimensional
complexity of the gray and white matter structures in the visual
cortex and LGN, we were unable to consistently identify which
enhancing spot in MRI corresponded to which subsonication
target in these two structures. This discrimination was confounded
by leakage of contrast agent from one target to another and one
imaging plane to another (particularly when the contrast leaked
into the sulci), and small shifts of a few mm in the position of the
head over the course of the experiments. While this discrimination
was possible in a few cases, in most cases we were not confident in
our ability to associate the enhancement with particular sub-
sonications. In the cingulate cortex in contrast, this discrimination
was relatively straightforward since the orientation of the cortical
structure was parallel to our imaging planes. Thus, in the 28
cingulate cortex targets, we were able to make this comparison.
However, we were not able to make this comparison for all
subsonication targets due to evident leakage of MRI contrast agent
between the targets. Thus, we compared MRI signal enhancement
at the subsonication with the biggest enhancement to the
corresponding harmonic emissions signal.
Finally, we examined the T2*-weighted imaging obtained after
each session and identified whether or not hypointense spots were
produced at any of the subsonication targets, and whether they
correlated with the presence of broadband or ultraharmonic
emissions. This identification was often challenging, as the signal
changes induced with minor petechaie can be subtle; this
procedure was facilitated by registering the images to those
obtained in other sessions [32].
Sonication Optimization
Finally, we evaluated the feasibility of increasing the harmonic
emissions, and presumably the BBB disruption, in individual
subsonication targets where low signals were recorded. In these
tests, a multi-target sonication was applied at a nominal exposure
level as described above. We then analyzed the acoustic emissions
(Eq. 3) for each individual subsonication target to determine which
had no or only weak harmonic emissions signals. Those targets
were sonicated a second time with either a small increase in power
(corresponding to a pressure amplitude increase of 5–15 kPa), or
at the same power level but with five times the microbubble dose.
Subsonication targets that exhibited strong harmonic emissions
were not sonicated again. These experiments were performed over
several weekly sessions in monkeys #5–6. The procedures were
evaluated in 11 multi-target sonications in the cingulate cortex,
four of which at higher microbubble dose, and one in the visual
cortex. The sub-sonication targets were selected for a second
sonication solely based on the harmonic signal and not based on
the underlying structure.
We aimed with these experiments to determine whether
additional sonications could increase the harmonic emissions
signal above a threshold value where MRI contrast enhancement
was expected, based on the experiments described above. We also
compared the harmonic emissions signal strength for the first and
second sonications to determine whether any increase that we
produced was predictable. For experiments where the acoustic
power was increased, we compared our results with our pilot study
where a wide range of exposures were delivered in sequence to
individual targets. For experiments that increased the dose of
micro-bubbles, we investigated whether the harmonic emissions
signal strength would scale with the microbubble dosage.
Statistical Analysis
Each power spectrum obtained in the presence of microbubbles
was divided by the average spectrum obtained during 25 s
sonications that were performed before any microbubbles were
injected (10 or more waveforms per subsonication location)
according to Eq. 2. Harmonic emissions signals were relatively
constant over most of the sonications. Reported harmonic
emissions signals are the average microbubbles at the sonicated
targets are reported (typically the last 75 measurements). Reported
broadband and ultraharmonic signals are the maximum individual
measurement achieved among all the waveforms for that
sonication. The harmonic emission signals for different tissue
structures were compared using an unpaired, two-tailed t-test.
Additional analysis included least-squares regression and calcula-
tion of correlation coefficients.
Results
Pilot Studies
The acoustic emissions system was evaluated in initial, acute
tests in monkeys #1–2, where a range of pressure amplitudes were
tested and included exposures that purposely induced broadband
emissions. Fig. 2A shows typical acoustic emissions spectra for
cases with and without broadband emissions. Broadband emis-
sions were observed as signal at the resonant frequency of the
narrowband receiver transducers and were generally at sub-
stantially lower amplitude than the harmonic emissions. Note also
the flat frequency response of the recordings and the suppression
of the large signal at 220 kHz after normalizing the data to
Table 1. Acoustic power level used at the different targeted structures in each animal.
Monkey
Weekly
Sessions Sex, weight LGN Visual Cortex Cingulate Cortex Other
1 1 M 5 kg – – 0.4–4 W (N:4)
2 1 M, 7.5 kg – – 0.3–1.5 W (N:10)
3 5 M, 7 kg 0.81 [0.75–0.90] W
1 (N: 10) 0.65 [0.50–0.75] W (N: 6
2)– –
4 5 F, 7.5 kg 0.88 [0.65–1.20] W (N: 10) 0.68 [0.65–0.70] W (N: 10) 0.55 [0.20–0.85] W (N: 8) 0.70 [0.70–0.70] W (N: 2)
5 5 M, 13 kg 1.58 [0.85–1.90] W (N: 10) 0.63 [0.60–0.66] W (N: 9
3) – 1.59 [0.85–1.90] W (N: 9)
6 7 M, 3.75 kg 0.54 [0.50–0.60] W (N: 10) 0.37 [0.35–0.40] W (N: 10) 0.47 [0.41–0.55] W (N: 20) –
1Mean power of N sonications [range]. The pressure amplitude (Pa) estimates in the brain in kPa were found using the following relationship: Pa=223*(Power)
1/2.
2The visual cortex targets were not sonicated in the first session with this animal.
3Acoustic emissions data excluded from one sonication due to excessive electronic noise.
doi:10.1371/journal.pone.0045783.t001
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increase in signal for different frequency bands as a function of the
estimated pressure amplitude in the brain. A marked increase in
harmonic emissions was observed starting at around 250 kPa,
which increased linearly as the pressure amplitude was increased
at a rate of 0.1460.01 per kPa. Ultraharmonic (signal at 3/2 and
5/2 of the ultrasound frequency) and broadband emissions
occurred at higher pressure amplitudes than for harmonic
emissions, and their onset occurred at similar thresholds
(340 kPa) for this target.
Sonications were performed in monkey #2 to assess the
sensitivity of the system in detecting low-level broadband
emissions. Fig. 3 shows the results of this experiment. Of the ten
locations targeted, three were found to be enhancing in MRI with
contrast and had strong harmonic emissions signals. Two of these
targets exhibited broadband emissions with an SNR greater than 3
(Fig. 3A), with a hypointense spot evident in T2*-weighted
imaging detected for the location with the stronger emissions
(Fig. 3B). This location resulted in extensive petechaie in histology
(Fig. 3C). The location with the lower broadband emissions
signals, which were near our sensitivity limits (SNR=4.3), resulted
in a few tiny petechaie in the choroid plexus, which was located
slightly inferior to this target location. The locations that exhibited
no broadband emissions appeared normal in histology.
Acoustic Emissions-Based Control
After confirming the system performance in our pilot studies, we
utilized it as a basis to manually control the acoustic power level
during in a survival study in monkeys #3–6, which we performed
multi-target sonications. Example acoustic emissions recordings
and MRI findings from these experiments are shown in Fig. 4.
During treatment, we monitored in real-time the strength of the
harmonic emissions from all subsonications as a function of time
(Fig. 4A). The microbubble arrival in the targeted region was
apparent as a marked increase in relative harmonic emissions
,15–20 s after the start of the infusion. After the microbubbles
arrived, the signal remained at a steady level for the duration of
the sonication. The spectral data from each burst were also
displayed (Fig. 4B) and monitored to ensure that no broadband
emission occurred. The sonication was repeated at a higher power
level if strong harmonic emissions were not observed.
Overall, we found that in most cases we were able to use this
control to produce MRI contrast enhancement without broad-
band emissions that are indicative of tissue damage. Only 3/75
(4%) of the targets of interest for the safety study that were
centered on the LGN or visual cortex failed to produce detectable
BBB disruption, and only 17/114 (15%) of all the multi-target
sonications exhibited broadband emissions with an SNR greater
than three. When broadband emissions were observed, they were
typically only evident in a few of the bursts. Among the 1026
subsonication locations in these 114 multi-target sonications, over
84,000 individual bursts were applied. During the 17 sonications
that produced broadband emission, only 187 bursts had broad-
band signal at this level. Thus, overall only about 0.2% of the
bursts over these 22 sessions were delivered above the inertial
cavitation threshold.
Acoustic Emissions vs. MRI
When data from all multi-target sonications were analyzed, we
found that the strength of the harmonic emissions was predictive of
whether or not MRI-evident BBB disruption occurred. This ability
is evident in Fig. 5A, which plots the strength of the harmonic
emissions for sonications with and without MRI contrast
enhancement. The harmonic emissions were significantly higher
(P,0.001) for cases where MRI contrast enhancement was
detected. Ten of the multi-target sonications did not produce
any evident Gd-DTPA extravasation; their harmonic emissions
had a strength of 6 Np?Hz or less. Only 12/104 (11.5%)
sonications where Gd-DTPA extravasation was observed exhib-
ited harmonic emissions of less than 6 Np?Hz, which was then
used as a threshold for successful BBB disruption.
The strength of the harmonic and broadband emissions was also
compared (Fig. 5B–D). The risk for significant broadband
emissions in the visual cortex was predicted by the strength of
the harmonic emissions. With the exception of a single subsonica-
tion that overlapped a sulcus, broadband emissions appeared only
Figure 2. Acoustic emissions over a wide range of exposure levels. (A) Typical power spectra showing spectra with and without broadband
emission. The emissions recorded during sonication with microbubbles were normalized to baseline data obtained during identical sonications
without microbubbles according to Eq. 2. Wideband emission was observed as signal detected around 610 kHz (arrow), the resonant frequency of
our receiving transducers. (B) Mean acoustic emissions signal (6 S.D.) as a function of the estimated pressure amplitude in the brain for harmonic,
ultraharmonic and broadband emissions obtained in monkey #1 during a sonication where bursts were applied sequentially at increasing pressure
amplitudes. Between 200–400 kPa, the harmonic signal strength increased linearly as a function of pressure amplitude (R
2=0.92). The harmonic
signal increase per kPa was 0.1460.01 Np?Hz/kPa. The average signals from four bursts at each pressure amplitude are shown (mean 6 SD shown).
The arrows indicate the lowest pressures where the harmonic and broadband signals were observed with an SNR greater than 3. Broadband and
ultraharmonic emissions were only observed in these locations when the harmonic emissions were greater than 20 Np?Hz.
doi:10.1371/journal.pone.0045783.g002
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Thus, there was a window of harmonic signals between 6–20
Np?Hz where broadband emission was absent (i.e., ‘‘stable
cavitation’’); in all of these sonications successful BBB disruption
was achieved. This range also agrees with the data from our pilot
study (Fig. 2B). We therefore considered this range for safe
exposure levels as BBB disruption is expected and inertial
cavitation is unlikely.
The strength of the harmonic signals for different tissue
structures varied among the different targeted structures
(Fig. 5A), with sonication in the visual cortex (which always
included subsonications that spanned sulci) producing the largest
harmonic signals. The observed difference in harmonic emis-
sions signals was reflected in the strength of the MRI signal
enhancement after Gd-DTPA injection. Multi-target sonications
centered on the LGN generally exhibited patchy and weak
enhancement, while volumes in the cingulate and visual cortices
Figure 3. Acoustic emissions, MRI, and histology at different exposure levels. (A) Acoustic emissions, recorded during three single-target
sonications delivered to the cingulate cortex in monkey #2, showing the largest broadband emissions for these sonications (arrow). Only locations 2
and 3 exhibited strong harmonic emissions (harmonic signal strength: 4.1, 17.9 and 25.8 Np?Hz, for locations 1–3, respectively) and resulted in
contrast enhancement in MRI. Broadband emissions with an SNR greater than 3 were present at location 3 and at a much lower level at location 2,
but not at location 1. The estimated pressure amplitudes in the brain were 175 kPa at location 1 and 275 kPa at locations 2–3. (B) T2*-weighted
image acquired shortly after the sonications. A hypointense spot is only evident at location 3. (C) Light microscopy showing no petechaie or other
changes at location 1. Tiny petechaie were found in the choroid plexus, (in the lateral ventricle) which was just inferior to location 2. It is possible that
any changes in MRI resulting from petechaie at this location were missed because they occurred in the ventricle, which appears hypointense in our
T2*-weighted imaging. Extensive petechaie were evident in histology at location 3. These petechaie covered a region 3 mm in diameter, similar to
the half-intensity beam width of the focal zone of this TcMRgFUS device.
doi:10.1371/journal.pone.0045783.g003
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ment occurring in gray matter regions within the volumes.
We investigated this agreement in more detail by evaluating
each subsonication target individually. We found that the
harmonic signal was predictive of the level of signal enhancement
for the different targets. Examples of this agreement are shown in
Fig. 6. The magnitude of both the MRI signal enhancement and
the harmonic signal at each subsonication target depended
strongly on whether the target was in gray matter or white
matter, where little or no extravasation or relative harmonic signal
was observed. While low-level contrast enhancement was occa-
sionally observed in voxels that appeared to be largely white
matter, in most cases we could not exclude the possibility that this
enhancement came from extravasation in grey matter structures
partially contained within the MR imaging slice, or from leakage
of Gd-DTPA from an adjacent gray matter site. In only two multi-
target sonications were we confident that low-level contrast
extravasation was detected in purely white matter. In both cases,
the targets were sonicated two times at either an increased power
level or microbubble dosage (see below).
In the cingulate cortex sonications, we could always associate
the locations with the most MRI contrast enhancement to the
corresponding subsonication target and explore the correlation
between harmonic emissions quantitatively. Fig. 7 plots the
percent MRI signal increase after Gd-DTPA injection for these
subsonications or each of the 28 cingulate cortex sonications.
Overall, the strength of the MRI signal enhancement increased
non-linearly as the strength of the harmonics increased; a good
correlation (R
2=0.78) was observed with an exponential fit. The
relationship between the strength of the harmonic emissions and
the MRI enhancement level appeared to be consistent among
targets in both monkeys #4 and #6 and for cases where the
subsonication was targeted a second time with a higher pressure
amplitude or microbubble dose (see below).
Only 5/17 (29.5%) of the targets with broadband emissions
produced hypointense spots that were detected in a blind review
Figure 4. Example acoustic emissions and MRI for a multi-target sonication centered on the LGN in monkey #3. (A) Harmonic
emission signal strength as a function of time (212 kPa; Mean: mean signal 6 S.D. for the nine subsonications; Min./Max.: subsonications with smallest
and largest signals). The increase in emissions due to the arrival of the microbubbles at about 20 s is evident. Note also the constant level of
emissions over the duration of the rest of the sonication. Harmonic emissions greater than zero at time=0 were presumably due to microbubbles
present in the circulation from an earlier sonication. (B) Relative power spectra averaged between 25–140 s showing strong harmonic emissions
without evident broadband emissions. (C) T2-weighted image showing the location of the sonication. (D) MRI contrast enhancement observed in T1-
weighted MRI after Gd-DTPA injection (percent enhancement shown). The subsonication targets are indicated (‘+’ subsonication target with
strongest signals; ‘2’ target with smallest signals; ‘*’ others).
doi:10.1371/journal.pone.0045783.g004
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should note, however, that sulci always appeared hypointense in
the T2*-weighted imaging. If petechaie were produced there,
they would have been undetectable. The subsonications with
broadband emission were all part of multi-target sonications
centered on the visual cortex and occurred at 0.65 W and
above (estimated pressure amplitude in the brain 180 kPa or
greater). Eighty-eight percent (15/17) of the subsonication
targets with broadband emission were among the three most
lateral targets in the 363 grid and were consistent with being
targeted to a large vessel-containing sulcus or a large surface
vessel, suggesting that such vessels may have a lower inertial
cavitation threshold.
Ultraharmonic emissions were not useful for predicting BBB
disruption or damage. They were only occasionally observed (28/
1026 subsonications), and when they were seen, they were
detected only at exposure levels above the threshold for BBB
disruption. We detected broadband emissions along with the
ultraharmonic emissions in 10/28 (36%) of these subsonications.
Except for four cingulate subsonications, all ultraharmonic
emissions were observed during multi-target sonications centered
on the visual cortex.
Sonication Optimization
We attempted to increase the harmonic emissions (and
presumably the BBB disruption) at individual subsonications
that exhibited low signal by sonicating a second time at an
increased power level. This procedure was tested in seven of the
multi-target sonications in the cingulate or visual cortices. A
total of 47/63 of the subsonications in these multi-target
sonications had low harmonic emissions and were selected for
a second sonication; subsonications that had strong harmonic
emissions were not sonicated again. A small (5–15 kPa) increase
in pressure amplitude did increase the harmonic emission in the
second sonication in many of the subsonications, and that this
increase was often substantial. For example, in 38 of the
subsonication targets, the harmonic signal was initially less than
6N p ?Hz (where BBB disruption was not expected). We were
able to increase it above this value in 14/38 of these targets,
and the increase was always in the safe range defined above.
While the increase in harmonic signal per kPa was variable and
ranged from 20.8 to 1.5 Np?Hz, the mean value (0.2060.37
Np?Hz) was consistent with what was observed in monkey #1
(Fig. 2B). Example data from two targets where this procedure
was investigated are shown in Fig. 8A–B.
We also investigated whether low-level harmonic emissions
could be increased using a higher dose of microbubbles. This
procedure was tested in four multi-target sonications in the
cingulate cortex. A total of 23/36 of the subsonications had low
harmonic signal and were sonicated a second time at the same
power level, but with five times the micro-bubble dose. An
example showing data from this procedure is shown in Fig. 8C.
We found that this approach was effective at increasing the relative
harmonic signal and maintaining a safe exposure based on the
criteria defined above. This increase was also predictable - a linear
relationship was observed between the harmonic signal for the two
sonications (Fig. 9). This slope is consistent with a linear de-
pendence of the harmonic signal strength and microbubble dose,
as our measurements were log-transformed and ln(5)=1.6. A non-
zero y-intercept suggests that oscillating microbubbles were
perhaps present during the first sonication, but they produced
harmonics below the sensitivity of our detectors.
Figure 5. Harmonic emissions predict BBB disruption and safety limits. (A) Maximum harmonic emission signal strength achieved during
104 multi-target sonications that did and did not result in MRI contrast enhancement. Sonication at different tissue structures produced different
levels of harmonic emissions (*P,0.05; ***P,0.001). The greatest harmonic emissions were measured during sonication in the visual cortex. Contrast
enhancement was always observed when the harmonic signal strength was 6 Np?Hz or higher. (B–D) Broadband emission plotted as a function of
harmonic signal strength for 1026 subsonication targets in the three tissue structures. Red symbols indicate subsonications where the SNR of the
broadband emissions signals was greater than 3. Such emissions were only observed in sonications in the visual cortex, and with one exception, only
occurred when the harmonic emissions strength was greater than 20 Np?Hz.
doi:10.1371/journal.pone.0045783.g005
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The type of microbubble oscillation that occurs during
sonication can be characterized by the spectral content of
passively-recorded acoustic emissions originating from the oscil-
lating microbubbles [21]. We have demonstrated that the strength
of harmonic signal is predictive of both the onset and magnitude of
the MRI signal increase reflecting Gd-DTPA extravasation and
are indicative of the exposure parameters needed for robust BBB
permeabilization. For safe BBB disruption, broadband emissions
set an upper limit on the exposure parameters, as they are
a signature for inertial cavitation and tissue damage [10,11]. These
two signals collected during the sonications and the methodology
to quantify them form the basis to build controllers for cavitation-
based pharmacological therapies in the brain and elsewhere. Here,
we showed that reliable measurements could be obtained
transcranially in a relevant animal model with a clinical
TcMRgFUS system, and over 22 weekly sessions demonstrated
that by monitoring the emissions we could reliably ensure a safe
and effective outcome. These results are highly encouraging and
warrant evaluation of the method in patients.
In these experiments, the operator of the TcMRgFUS device
was part of the control loop that evaluated the acoustic emissions
and modified the power level for each sonication. Improved
outcomes may be achieved using automated, computer-based
control of the sonications [17,42]. With such control, one could
automatically adjust the exposure levels on a burst-by-burst level
to rapidly achieve a desired harmonic emissions signal strength,
and automatically lower or stop the sonication if broadband
emissions were detected. The quality of the data recorded here,
along with the correlations we observed between the emissions
signals and the resulting BBB disruption suggest that this will be
readily achievable. However, our data suggest that one may not be
able to easily predict the response to a change in acoustic power, as
we observed substantial variability among the different targets
after sonicating a second time at only a slightly higher level. This
variability is perhaps not surprising, as the effective volume of the
focal region will increase at higher pressure amplitudes and will
include different structures with different vessel densities (and
microbubble concentrations). Nevertheless, using small increments
in acoustic power should ensure that such control would be an
effective means to ensure a safe and effective procedure.
Sonicating a second time with an increased microbubble dose
appeared to be a more predictable means to increase the harmonic
emissions.
For this control to be translated to patients, we need to ensure
that the measurements can be achieved through the thicker
human skull. Our harmonic emissions data are promising for this
translation. The relatively broad window in harmonic signals
where safe BBB permeabilization was observed was substantially
above the noise floor of our monitoring system. A harmonic
emissions signal of 6 Np?Hz, the level above which where BBB
disruption was always found, corresponded to an SNR of
approximately 10. If we assume that a human skull is 5 mm
thicker than a macaque skull, using an attenuation coefficient of
70 Np/m at 840 kHz we would expect an attenuation of the
relative harmonic signals at worst by a factor of two. Even with this
attenuation we could detect harmonic signals with SNR greater
than five. However, measurements using a higher-frequency
TcMRgFUS clinical system could be challenging since acoustic
attenuation increases with frequency. In contrast to the harmonics,
the broadband signals were substantially weaker, and it may be
challenging to detect them in a human. For example, in our pilot
study, petechaie were found in histology with a broadband signal
of only 5.6 Np?Hz, (SNR=4.3). Our acoustic emissions measure-
ments were also not sensitive to harmonic emissions during
sonication in white matter. In our previous study, we found that
the BBB can be disrupted in white matter even when no harmonic
emissions or MRI contrast enhancement is observed [32]. As
described below, we suspect this is due to the white matter’s lower
vascular density, leading to a lower microbubble concentration
within the focal region. If that is the case, a more sensitive detector
may be able to measure the emissions.
We anticipate that we can significantly improve the sensitivity of
our measurements by optimizing the design of our detectors. For
example, we expect that we could achieve a two-fold increase in
sensitivity by simply aiming our receiving transducers at the
Figure 6. Comparison of harmonic emissions and MRI contrast enhancement at individual subsonications during six multi-target
sonications in the cingulate cortex in monkey #4. (A) Axial T2-weighted FSE images showing the location of the subsonication targets, which
included the cingulate cortex and adjacent white matter. Gray matter is bright compared to white matter in these images. (B) Images showing the
percent increase in MRI signal after Gd-DTPA injection and the harmonic emission measurements (in Np?Hz) noted at each subsonication target.
Targets where the SNR of the harmonic emissions was less than 3 (circled) did not result in detectable MRI contrast enhancement. The magnitude of
the emissions agreed qualitatively with that of the contrast enhancement. Little or no contrast enhancement or harmonic emission was observed in
subsonications that were targeted in white matter. (scale bar: percent MRI signal increase after Gd-DTPA injection). (C) Spectra showing only
harmonic emissions at each subsonication for the multi-target sonication in (A) noted with an orange ‘‘*’’. The harmonic emissions signal strength
(HS) is noted for each subsonication.
doi:10.1371/journal.pone.0045783.g006
Figure 7. MRI signal enhancement after Gd-DTPA injection
plotted as a function of the harmonic emissions signal
strength. Data are shown for individual subsonication targets
delivered in the cingulate cortex in monkeys #4 and #6. The MRI
enhancement was found in a 363 voxel ROI centered on the
subsonication target. The MRI signal increased nonlinearly as a function
of the strength of the harmonic emission. A good correlation (R
2: 0.78)
was found in a fit of the data to an exponential (solid line; dotted lines:
95% confidence intervals). Data shown are for the subsonication target
that exhibited the greatest MRI signal enhancement for each of 28
multi-target sonications that were performed in the cingulate cortex in
this study and included results from experiments where a second
sonication was applied at either a higher power level or with an
increased microbubble dose.
doi:10.1371/journal.pone.0045783.g007
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outside of the -3dB region of the sensitivity profile of the receiver
transducers. Additional improvement may be achieved by using
multiple detectors, or by attaching them to a positioning system to
maximize the sensitivity for each target. The use of arrays of
receivers and passive imaging reconstruction methods [43] to map
the microbubble activity within the brain in TcMRgFUS systems
[44,45] will further improve our results. In the present study, with
only two detectors we could only assume that the signals we
recorded were coming from microbubble activity in the focal
region. This is a reasonable assumption since we have not
observed any BBB disruption or damage outside of the targeted
volumes in these experiments or in our earlier work [32], but it
would be desirable from a safety perspective to ensure that the
activity is occurring only at the focal region.
Our measurements may also be sensitive to signals arising from
nonlinear propagation due to the presence of the microbubbles in
the beam path of the TcMRgFUS device [46]. While normalizing
the acoustic emissions to baseline data obtained without micro-
bubbles will remove the contributions from the transmitted and
reflected wave the presence of the microbubbles can effectively
change the nonlinearity of the tissue and add harmonic activity to
our measurements. With the large geometric gain of the
TcMRgFUS device, the relatively low microbubble concentration,
and the low frequency of the TcMRgFUS device, these
contributions might be expected to be small compared to
emissions from the focal region. However, they should be
explored. Additional uncertainties in the magnitude of the
emissions arising from differences in skull thickness between
subjects and from the sensitivity profile of the receiver transducers
should also be taken into account.
Despite these uncertainties, we found a good correlation with
the strength of the harmonic emissions to the strength of the MRI
enhancement after the administration of Gd-DTPA, at least in the
cingulate cortex. As the MRI contrast enhancement level after
BBB disruption can be correlated to drug concentrations in the
brain [47], this finding suggests that one may be able to predict the
amount of drug delivered to each target without having to perform
contrast-enhanced imaging. This would be desirable, since being
able to perform this procedure without an MRI would reduce its
costs and complexity. However, this ability might be confounded
by the different responses to the sonications we observed at
different brain structures. These differences were most evident in
white matter, where little or no acoustic emissions or BBB
permeabilization were observed, and in the visual cortex targets
that included sulci, where the acoustic emissions and BBB
permeabilization were substantially larger.
Figure 8. Sonication optimization. (A) Example where the pressure amplitude was increased by 10 kPa at select subsonications in a visual cortex
sonication in monkey #4. The harmonic emissions achieved during the first and second sonications (in Np?Hz) are noted for each subsonication
target. Two of five targets that were sonicated twice overlapped with a sulcus (red circles) and showed a large increase in harmonic emissions with
the second sonication. From the other targets only one showed significant increase (circled). (B) Similar experiment performed in the cingulate cortex
in monkey #5. In this example the pressure amplitude was increased by 15 kPa for the second sonication. Three of the locations showed a strong
increase in harmonic emissions (circled). (C) Similar experiment performed in the cingulate cortex in monkey #5, but instead of increasing the
pressure amplitude, the second sonication used five times the microbubble dose (circles indicate the most pronounced increase in harmonic
emissions). Arrows indicate strong contrast enhancement at the targets with pronounced increase in the harmonic emissions (Left images: T2-
weighted images showing the location of the targeted volumes and the ROI; Right images: images showing contrast enhancement in T1-weighted
images after Gd-DTPA injection).
doi:10.1371/journal.pone.0045783.g008
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white matter, is explained by differences in vascularity [48].
Differences in blood flow and in the interstitial space may also
impact the sonications and resulting extravasation of imaging
tracer or drug. It is clear that treatment planning imaging, at least,
will be necessary to interpret the acoustic emissions recorded at
each target. Advanced imaging methods to estimate local
variations in vascularity, vessel size, blood flow, and other
functional imaging methods may also prove useful in interpreting
the measurements.
Differences in vessel properties may also be important with
respect to safety. A lower cavitation threshold was evident for the
peripheral subsonications in the visual cortex and was consistent
with being targeted to a large vessel-containing sulcus or a large
surface vessel. Having a lower inertial cavitation threshold in
larger vessels would agree with experimental results in vessel-
mimicking tunnels [49] and might occur due to higher micro-
bubble numbers, lower bubble-to-bubble distances, or from less
restrictions on the magnitude of bubble oscillations. If this is the
case, it might restrict the design of TcMRgFUS systems for BBB
disruption. For example, a transducer with a smaller geometric
gain (i.e. not hemispherical) will have an elongated focal region,
and it may not be able to target superficial regions without
including vulnerable regions in the focus.
Our findings are in agreement with other studies that have
evaluated acoustic emissions recordings during ultrasound-induced
BBB disruption. In a prior study in rabbits [10], the presence of
large harmonic emissions signals was also found to be predictive of
whether or not BBB disruption occurred, and their strength was
correlated with MRI signal intensity increases after Gd-DTPA
administration. That work also found a correlation between
broadband emissions and the production of petechaie in the brain.
While we do not have histological correlation with our acoustic
emissions measurements (as monkeys #3–6 were not euthanized
after the sonications), we did not find changes in T2*-weighted
imaging in the absence of broadband emissions. It would be
interesting to examine whether the different levels of harmonic
emission correlate with any changes evident in histology. Based on
the results of our prior study that did include histology [32], we do
not expect there to be any significant changes in the monkey brain
when T2*-weighted imaging is normal. Tung et al. also observed
strong harmonic emissions during BBB disruption in mice and
correlated broadband emissions with histological damage [11].
That group has also shown feasibility of transcranially recording
emissions in monkeys [50]. Finally, O’Reilly et al. has tested an
automated, computer-controlled control method, where the
acoustic power was increased sequentially until ultraharmonic
emissions were detected, at which point the pressure amplitude
was dropped to a lower value [17]. They found some minor
petechaie in some cases, which is consistent with our findings that
ultraharmonic emissions, when present, were often observed along
with broadband emissions. That approach did not seem to be
possible here, as ultraharmonic emissions were rarely observed
outside of the visual cortex sonications.
Conclusions
We have demonstrated that increasing the sonication exposure
level until strong harmonic emissions are detected is an effective
way to ensure a safe exposure level for FUS-induced BBB
disruption. We also observed that the strength of these emissions is
correlated with the extravasation of an MRI contrast agent that
normally does not penetrate the blood-brain barrier. These results
are promising for clinical translation of this technique, as the
experiments were performed using a clinical TcMRgFUS device
and a relevant animal model. Apart from its utility in clinical
practice, it is anticipated that the method and procedure presented
could be an invaluable tool for pre-clinical and neuroscience
research to control the delivery of therapeutic, functional, or
diagnostic compounds to brain targets at a desired concentration.
Overall, the present work describes a basis for ‘‘smart therapeutic
ultrasound systems’’ that can control bubble dynamics in real-time
and in vivo to obtain reproducible, safe, and uniform permeabi-
lization of vascular barriers in the brain, and potentially elsewhere.
Based on the presented data and analysis the next step is to
develop a fully automatic feedback controller of the sonication
exposure settings. Such systems are expected to be an important
methodology to asses bubble kinetics and provide treatment
control. This control is anticipated to be especially important at
diseased targets such as tumors, where local anomalies in
vascularity and flow are frequent.
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Figure 9. Increase in harmonic emissions strength with in-
creased microbubble dose. Individual subsonications with low
harmonic emissions signals were sonicated again with five times the
microbubble dose. Signals recorded during the second sonication
increased substantially; all but one increased to a level above 6 Np?Hz,
a level where MRI-evident BBB disruption is expected based on results
in Fig. 5. The two measurements were correlated (R
2: 0.65). The
measured slope indicates that the strength of the harmonic emissions is
proportional to the number of oscillating microbubbles, since the
signals were log-transformed (Eq. 3, log(5)=1.6). A non-zero Y-intercept
suggests that there may have been low-level harmonic emissions
during the first sonication that were below our detection threshold.
doi:10.1371/journal.pone.0045783.g009
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